Vulvar squamous cell carcinoma

Expert Review of Obstetrics and Gynecology

Volumn 4, Issue 6, 2009, Pages 659-672

  Van de Nieuwenhof, Hedwig P ^a   Oonk, Maaike hm ^a   de Hullu, Joanne A ^a   Van Der Zee, Ate gj ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

prevention; prognostic factor; radiotherapy; recurrence pattern; sentinel lymph node procedure; surgery; vulvar squamous cell carcinoma

Indexed keywords

EID: 78149360536     PISSN: 17474108     EISSN: 17474116     Source Type: Journal    
DOI: 10.1586/eog.09.58     Document Type: Article

References (108)

1. van de Nieuwenhof HP, Massuger LF, van der Avoort I et al. Vulvar squamous cell carcinoma development after diagnosis of VIN increases with age. Eur. J. Cancer 45 (5), 851–856 (2009).
2. Al-Ghamdi A, Freedman D, Miller D et al. Vulvar squamous cell carcinoma in young women: a clinicopathologic study of 21 cases. Gynecol. Oncol. 84 (1), 94–101 (2002).
3. Hampl M, Deckers-Figiel S, Hampl JA, Rein D, Bender HG. New aspects of vulvar cancer: changes in localization and age of onset. Gynecol. Oncol. 109 (3), 340–345 (2008).
4. Ansink A. Vulvar squamous cell carcinoma. Semin. Dermatol. 15 (1), 51–59 (1996).
5. Madsen BS, Jensen HL, van den Brule AJ, Wohlfahrt J, Frisch M. Risk factors for invasive squamous cell carcinoma of the vulva and vagina – population-based case–control study in Denmark. Int. J. Cancer 122 (12), 2827–2834 (2008).
6. Hacker NF. Vulvar Cancer. In: Practical Gynaecologic Oncology. Berek S, Hacker NF (Eds). Lippincott Williams & Wilkins, PA, USA, 543–583 (2005).
7. Klinkert J, Lammes FB. [Unnecessary delay in vulvar carcinoma]. Ned. Tijdschr. Geneeskd. 135 (31), 1385–1388 (1991).
8. Hoevenaars BM, van der Avoort I, de Wilde PC et al. A panel of p16(INK4A), MIB1 and p53 proteins can distinguish between the 2 pathways leading to vulvar squamous cell carcinoma. Int. J. Cancer 123 (12), 2767–2773 (2008).
9. van der Avoort I, Shirango H, Hoevenaars BM et al. Vulvar squamous cell carcinoma is a multifactorial disease following two separate and independent pathways. Int. J. Gynecol. Pathol. 25 (1), 22–29 (2006).
10. Sideri M, Jones RW, Wilkinson EJ et al. Squamous vulvar intraepithelial neoplasia: 2004 modified terminology, ISSVD Vulvar Oncology Subcommittee. J. Reprod. Med. 50 (11), 807–810 (2005).
11. van de Nieuwenhof HP, van Kempen LC, de Hullu JA et al. The etiologic role of HPV in vulvar squamous cell carcinoma fine tuned. Cancer Epidemiol. Biomarkers Prev. 18 (7), 2061–2067 (2009).
12. Hart WR. Vulvar intraepithelial neoplasia: historical aspects and current status. Int. J. Gynecol. Pathol. 20 (1), 16–30 (2001).
13. Yang B, Hart WR. Vulvar intraepithelial neoplasia of the simplex (differentiated) type: a clinicopathologic study including analysis of HPV and p53 expression. Am. J. Surg. Pathol. 24 (3), 429–441 (2000).
14. Lanneau GS, Argenta PA, Lanneau MS et al. Vulvar cancer in young women: demographic features and outcome evaluation. Am. J. Obstet. Gynecol. 200 (6), 645.e1–645.e5 (2009).
15. de Bie RP, van de Nieuwenhof HP, Bekkers RL et al. Patients with usual vulvar intraepithelial neoplasia-related vulvar cancer have an increased risk of cervical abnormalities. Br. J. Cancer 101 (1), 27–31 (2009).
16. Dursun P, Ayhan A, Tarhan NC, Coban G, Kuscu E. Cerebellar metastasis in squamous cell vulvar carcinoma. Arch. Gynecol. Obstet. 279 (1), 69–71 (2009).
17. DiSaia PJ, Creasman WT, Rich WM. An alternate approach to early cancer of the vulva. Am. J. Obstet. Gynecol. 133 (7), 825–832 (1979).
18. Six L, Polterauer S, Grimm C et al. C-reactive protein serum levels are closely associated with lymph node status, but not with prognosis in patients with vulvar cancer. Eur. J. Obstet. Gynecol. Reprod. Biol. 137 (2), 217–221 (2008).
19. Maggino T, Landoni F, Sartori E et al. Patterns of recurrence in patients with squamous cell carcinoma of the vulva. A multicenter CTF Study. Cancer 89 (1), 116–122 (2000).
20. Woolderink JM, de Bock GH, de Hullu JA, Davy MJ, van der Zee AG, Mourits MJ. Patterns and frequency of recurrences of squamous cell carcinoma of the vulva. Gynecol. Oncol. 103 (1), 293–299 (2006).
21. Blecharz P, Karolewski K, Bieda T et al. Prognostic factors in patients with carcinoma of the vulva – our own experience and literature review. Eur. J. Gynaecol. Oncol. 29 (3), 260–263 (2008).
22. de Hullu JA, Hollema H, Lolkema S et al. Vulvar carcinoma. The price of less radical surgery. Cancer 95 (11), 2331–2338 (2002).
23. Hopkins MP, Reid GC, Johnston CM, Morley GW. A comparison of staging systems for squamous cell carcinoma of the vulva. Gynecol. Oncol. 47 (1), 34–37 (1992).
24. FIGO Committee on Gynecological Oncology. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int. J. Gynecol. Obstet. 105, 103–104 (2009).
25. Hacker NF. Revised FIGO staging for carcinoma of the vulva. Int. J. Gynaecol. Obstet. 105 (2), 105–106 (2009).
26. Barbera L, Thomas G, Elit L et al. Treating vulvar cancer in the new millennium: are patients receiving optimal care? Gynecol. Oncol. 109 (1), 71–75 (2008).
27. Rouzier R, Haddad B, Atallah D, Dubois P, Paniel BJ. Surgery for vulvar cancer. Clin. Obstet. Gynecol. 48 (4), 869–878 (2005).
28. Way S. The modern treatment of carcinoma of the vulva. Med. Press 227 (14), 318–321 (1952).
29. de Hullu JA, van der Zee AG. Surgery and radiotherapy in vulvar cancer. Crit. Rev. Oncol. Hematol. 60 (1), 38–58 (2006).
30. Carlson JW, Kauderer J, Walker JL et al. A randomized Phase III trial of VH fibrin sealant to reduce lymphedema after inguinal lymph node dissection: a Gynecologic Oncology Group study. Gynecol. Oncol. 110 (1), 76–82 (2008).
31. de Hullu JA, van der Avoort I, Oonk MH, van der Zee AG. Management of vulvar cancers. Eur. J. Surg. Oncol. 32 (8), 825–831 (2006).
32. Magrina JF, Gonzalez-Bosquet J, Weaver AL et al. Squamous cell carcinoma of the vulva stage IA: long-term results. Gynecol. Oncol. 76 (1), 24–27 (2000).
33. Burke TW, Levenback C, Coleman RL, Morris M, Silva EG, Gershenson DM. Surgical therapy of T1 and T2 vulvar carcinoma: further experience with radical wide excision and selective inguinal lymphadenectomy. Gynecol. Oncol. 57 (2), 215–220 (1995).
34. Farias-Eisner R, Cirisano FD, Grouse D et al. Conservative and individualized surgery for early squamous carcinoma of the vulva: the treatment of choice for stage I and II (T1–2N0–1M0) disease. Gynecol. Oncol. 53 (1), 55–58 (1994).
35. DeSimone CP, Van Ness JS, Cooper AL et al. The treatment of lateral T1 and T2 squamous cell carcinomas of the vulva confined to the labium majus or minus. Gynecol. Oncol. 104 (2), 390–395 (2007).
36. Yoder BJ, Rufforny I, Massoll NA, Wilkinson EJ. Stage IA vulvar squamous cell carcinoma: an analysis of tumor invasive characteristics and risk. Am. J. Surg. Pathol. 32 (5), 765–772 (2008).
37. Tantipalakorn C, Robertson G, Marsden DE, Gebski V, Hacker NF. Outcome and patterns of recurrence for International Federation of Gynecology and Obstetrics (FIGO) stages I and II squamous cell vulvar cancer. Obstet. Gynecol. 113 (4), 895–901 (2009).
38. Rouzier R, Haddad B, Plantier F, Dubois P, Pelisse M, Paniel BJ. Local relapse in patients treated for squamous cell vulvar carcinoma: incidence and prognostic value. Obstet. Gynecol. 100 (6), 1159–1167 (2002).
39. Gaarenstroom KN, Kenter GG, Trimbos JB et al. Postoperative complications after vulvectomy and inguinofemoral lymphadenectomy using separate groin incisions. Int. J. Gynecol. Cancer 13 (4), 522–527 (2003).
40. Byron SC, Lamb EJ, Yonemoto RH, Kase S. Radical inguinal node dissection in the treatment of cancer. Surg. Gynecol. Obstet. 114, 401–408 (1962).
41. van der Velden J, Schilthuis MS, Hyde SE, Ten Kate FJ, Burger MP. Squamous cell cancer of the vulva with occult lymph node metastases in the groin: the impact of surgical technique on recurrence pattern and survival. Int. J. Gynecol. Cancer 14 (4), 633–638 (2004).
42. Iversen T, Aas M. Lymph drainage from the vulva. Gynecol. Oncol. 16 (2), 179–189 (1983).
43. Morton DL, Thompson JF, Cochran AJ et al. Sentinel-node biopsy or nodal observation in melanoma. N. Engl. J. Med. 355 (13), 1307–1317 (2006).
44. Veronesi U, Paganelli G, Viale G et al. Sentinel-lymph node biopsy as a staging procedure in breast cancer: update of a randomised controlled study. Lancet Oncol. 7 (12), 983–990 (2006).
45. de Hullu JA, Hollema H, Piers DA et al. Sentinel lymph node procedure is highly accurate in squamous cell carcinoma of the vulva. J. Clin. Oncol. 18 (15), 2811–2816 (2000).
46. Oonk MH, Hollema H, de Hullu JA, van der Zee AG. Prediction of lymph node metastases in vulvar cancer: a review. Int. J. Gynecol. Cancer 16 (3), 963–971 (2006).
47. Hall TB, Barton DP, Trott PA et al. The role of ultrasound-guided cytology of groin lymph nodes in the management of squamous cell carcinoma of the vulva: 5-year experience in 44 patients. Clin. Radiol. 58 (5), 367–371 (2003).
48. Ansink AC, Sie-Go DM, van der Velden et al. Identification of sentinel lymph nodes in vulvar carcinoma patients with the aid of a patent blue V injection: a multicenter study. Cancer 86 (4), 652–656 (1999).
49. Hampl M, Hantschmann P, Michels W, Hillemanns P. Validation of the accuracy of the sentinel lymph node procedure in patients with vulvar cancer: results of a multicenter study in Germany. Gynecol. Oncol. 111 (2), 282–288 (2008).
50. De Cicco C, Sideri M, Bartolomei M et al. Sentinel node biopsy in early vulvar cancer. Br. J. Cancer 82 (2), 295–299 (2000).
51. Levenback C, Coleman RL, Burke TW, Bodurka-Bevers D, Wolf JK, Gershenson DM. Intraoperative lymphatic mapping and sentinel node identification with blue dye in patients with vulvar cancer. Gynecol. Oncol. 83 (2), 276–281 (2001).
52. Merisio C, Berretta R, Gualdi M et al. Radioguided sentinel lymph node detection in vulvar cancer. Int. J. Gynecol. Cancer 15 (3), 493–497 (2005).
53. Moore RG, DePasquale SE, Steinhoff MM et al. Sentinel node identification and the ability to detect metastatic tumor to inguinal lymph nodes in squamous cell cancer of the vulva. Gynecol. Oncol. 89 (3), 475–479 (2003).
54. Puig-Tintore LM, Ordi J, Vidal-Sicart S et al. Further data on the usefulness of sentinel lymph node identification and ultrastaging in vulvar squamous cell carcinoma. Gynecol. Oncol. 88 (1), 29–34 (2003).
55. Rob L, Robova H, Pluta M et al. Further data on sentinel lymph node mapping in vulvar cancer by blue dye and radiocolloid Tc99. Int. J. Gynecol. Cancer 17 (1), 147–153 (2007).
56. Sliutz G, Reinthaller A, Lantzsch T et al. Lymphatic mapping of sentinel nodes in early vulvar cancer. Gynecol. Oncol. 84 (3), 449–452 (2002).
57. Terada KY, Shimizu DM, Jiang CS, Wong JH. Outcomes for patients with T1 squamous cell cancer of the vulva undergoing sentinel node biopsy. Gynecol. Oncol. 102 (2), 200–203 (2006).
58. Levenback CF, van der Zee AG, Rob L et al. Sentinel lymph node biopsy in patients with gynecologic cancers. Expert panel statement from the International Sentinel Node Society Meeting, February 21, 2008. Gynecol. Oncol. 114 (2), 151–156 (2009).
59. Brunner AH, Polterauer S, Tempfer C et al. The accuracy of intraoperative frozen section of the inguinal sentinel lymph node in vulvar cancer. Anticancer Res. 28 (6B), 4091–4094 (2008).
60. van der Zee AG, Oonk MH, de Hullu JA et al. Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. J. Clin. Oncol. 26 (6), 884–889 (2008).
61. Knopp S, Nesland JM, Trope C. SLNB and the importance of micrometastases in vulvar squamous cell carcinoma. Surg. Oncol. 17 (3), 219–225 (2008).
62. de Hullu JA, Oonk MH, Ansink AC, Hollema H, Jager PL, van der Zee AG. Pitfalls in the sentinel lymph node procedure in vulvar cancer. Gynecol. Oncol. 94 (1), 10–15 (2004).
63. Oonk MH, van Os MA, de Bock GH, de Hullu JA, Ansink AC, van der Zee AG. A comparison of quality of life between vulvar cancer patients after sentinel lymph node procedure only and inguinofemoral lymphadenectomy. Gynecol. Oncol. 113 (3), 301–305 (2009).
64. Hyde SE, Valmadre S, Hacker NF, Schilthuis MS, Grant PT, van der Velden J. Squamous cell carcinoma of the vulva with bulky positive groin nodes-nodal debulking versus full groin dissection prior to radiation therapy. Int. J. Gynecol. Cancer 17 (1), 154–158 (2007).
65. Blake P. Radiotherapy and chemoradiotherapy for carcinoma of the vulva. Best Pract. Res. Clin. Obstet. Gynaecol. 17 (4), 649–661 (2003).
66. de Mooij Y., Burger MP, Schilthuis MS, Buist M, van der Velden. Partial urethral resection in the surgical treatment of vulvar cancer does not have a significant impact on urinary continence. A confirmation of an authority-based opinion. Int. J. Gynecol. Cancer 17 (1), 294–297 (2007).
67. Beriwal S, Coon D, Heron DE et al. Preoperative intensity-modulated radiotherapy and chemotherapy for locally advanced vulvar carcinoma. Gynecol. Oncol. 109 (2), 291–295 (2008).
68. Gadducci A, Cionini L, Romanini A, Fanucchi A, Genazzani AR. Old and new perspectives in the management of high-risk, locally advanced or recurrent, and metastatic vulvar cancer. Crit. Rev. Oncol. Hematol. 60 (3), 227–241 (2006).
69. Moore DH, Thomas GM, Montana GS, Saxer A, Gallup DG, Olt G. Preoperative chemoradiation for advanced vulvar cancer: a Phase II study of the Gynecologic Oncology Group. Int. J. Radiat. Oncol. Biol. Phys. 42 (1), 79–85 (1998).
70. van Doorn HC, Ansink A, Verhaar-Langereis M, Stalpers L. Neoadjuvant chemoradiation for advanced primary vulvar cancer. Cochrane Database Syst. Rev. 3, CD003752 (2006).
71. Katz A, Eifel PJ, Jhingran A, Levenback CF. The role of radiation therapy in preventing regional recurrences of invasive squamous cell carcinoma of the vulva. Int. J. Radiat. Oncol. Biol. Phys. 57 (2), 409–418 (2003).
72. Parthasarathy A, Cheung MK, Osann K et al. The benefit of adjuvant radiation therapy in single-node-positive squamous cell vulvar carcinoma. Gynecol. Oncol. 103 (3), 1095–1099 (2006).
73. Gaffney DK, Du BA, Narayan K et al. Patterns of care for radiotherapy in vulvar cancer: a gynecologic cancer intergroup study. Int. J. Gynecol. Cancer 19 (1), 163–167 (2009).
74. Fons G, Groenen SM, Oonk MH et al. Adjuvant radiotherapy in patients with vulvar cancer and one intra capsular lymph node metastasis is not beneficial. Gynecol. Oncol. 114 (2), 343–345 (2009).
75. van der Velden J, Ansink A. Primary groin irradiation vs primary groin surgery for early vulvar cancer. Cochrane Database Syst. Rev. 4, CD002224 (2001).
76. Jackson KS, Fankam EF, Das N et al. Unilateral groin and pelvic irradiation for unilaterally node-positive women with vulval carcinoma. Int. J. Gynecol. Cancer 16 (1), 283–287 (2006).
77. Montana GS, Thomas GM, Moore DH et al. Preoperative chemo-radiation for carcinoma of the vulva with N2/N3 nodes: a gynecologic oncology group study. Int. J. Radiat. Oncol. Biol. Phys. 48 (4), 1007–1013 (2000).
78. Moore DH. Chemotherapy and radiation therapy in the treatment of squamous cell carcinoma of the vulva: are two therapies better than one? Gynecol. Oncol. 113 (3), 379–383 (2009).
79. Bellati F, Angioli R, Manci N et al. Single agent cisplatin chemotherapy in surgically resected vulvar cancer patients with multiple inguinal lymph node metastases. Gynecol. Oncol. 96 (1), 227–231 (2005).
80. Preti M, Ronco G, Ghiringhello B, Micheletti L. Recurrent squamous cell carcinoma of the vulva: clinicopathologic determinants identifying low risk patients. Cancer 88 (8), 1869–1876 (2000).
81. Lataifeh I, Nascimento MC, Nicklin JL, Perrin LC, Crandon AJ, Obermair A. Patterns of recurrence and disease-free survival in advanced squamous cell carcinoma of the vulva. Gynecol. Oncol. 95 (3), 701–705 (2004).
82. Gonzalez Bosquet J, Magrina JF, Gaffey TA et al. Long-term survival and disease recurrence in patients with primary squamous cell carcinoma of the vulva. Gynecol. Oncol. 97 (3), 828–833 (2005).
83. Fonseca-Moutinho JA. Recurrent vulvar cancer. Clin. Obstet. Gynecol. 48 (4), 879–883 (2005).
84. Chan JK, Sugiyama V, Pham H et al. Margin distance and other clinico-pathologic prognostic factors in vulvar carcinoma: a multivariate analysis. Gynecol. Oncol. 104 (3), 636–641 (2007).
85. Fonseca-Moutinho JA, Coelho MC, Silva DP. Vulvar squamous cell carcinoma. Prognostic factors for local recurrence after primary en bloc radical vulvectomy and bilateral groin dissection. J. Reprod. Med. 45 (8), 672–678 (2000).
86. Spiryda LB, Fuller AF, Goodman A. Aggressive locally recurrent vulvar cancer: review of cases presented to Massachusetts General Hospital 1990 to present. Int. J. Gynecol. Cancer 15 (5), 884–889 (2005).
87. Eva LJ, Ganesan R, Chan KK, Honest H, Malik S, Luesley DM. Vulval squamous cell carcinoma occurring on a background of differentiated vulval intraepithelial neoplasia is more likely to recur: a review of 154 cases. J. Reprod. Med. 53 (6), 397–401 (2008).
88. Weikel W, Schmidt M, Steiner E, Knapstein PG, Koelbl H. Surgical therapy of recurrent vulvar cancer. Am. J. Obstet. Gynecol. 195 (5), 1293–1302 (2006).
89. Cheng X, Zang R, Wu X, Li Z, Cai S, Zhang Z. Recurrence patterns and prognostic factors in Chinese patients with squamous cell carcinoma of the vulva treated with primary surgery. Int. J. Gynecol. Cancer 19 (1), 158–162 (2009).
90. Raspagliesi F, Hanozet F, Ditto A et al. Clinical and pathological prognostic factors in squamous cell carcinoma of the vulva. Gynecol. Oncol. 102 (2), 333–337 (2006).
91. Stehman FB, Ali S, DiSaia PJ. Node count and groin recurrence in early vulvar cancer: A Gynecologic Oncology Group study. Gynecol. Oncol. 113 (1), 52–56 (2009).
92. Le T, Elsugi R, Hopkins L, Faught W, Fung-Kee-Fung M. The definition of optimal inguinal femoral nodal dissection in the management of vulva squamous cell carcinoma. Ann. Surg. Oncol. 14 (7), 2128–2132 (2007).
93. Kumar S, Shah JP, Bryant CS, Imudia AN, Morris RT, Malone JM Jr. A comparison of younger vs older women with vulvar cancer in the United States. Am. J. Obstet. Gynecol. 200 (5), E52 –E55 (2009).
94. Bloss JD, Liao SY, Wilczynski SP et al. Clinical and histologic features of vulvar carcinomas analyzed for human papillomavirus status: evidence that squamous cell carcinoma of the vulva has more than one etiology. Hum. Pathol. 22 (7), 711–718 (1991).
95. Pinto AP, Signorello LB, Crum CP, Harlow BL, Abrao F, Villa LL. Squamous cell carcinoma of the vulva in Brazil: prognostic importance of host and viral variables. Gynecol. Oncol. 74 (1), 61–67 (1999).
96. Knopp S, Trope C, Nesland JM, Holm R. A review of molecular pathological markers in vulvar carcinoma: lack of application in clinical practice. J. Clin. Pathol. 62 (3), 212–218 (2009).
97. Ault KA. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 369 (9576), 1861–1868 (2007).
98. Paavonen J, Jenkins D, Bosch FX et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a Phase III double-blind, randomised controlled trial. Lancet 369 (9580), 2161–2170 (2007).
99. US FDA. FDA Approves Expanded Uses for Gardasil to Include Preventing Certain Vulvar and Vaginal Cancers. FDA Press Release, 18 September 2008.
100. De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int. J. Cancer 24 (7), 1626–1636 (2008).
101. Giuliano AR, Tortolero-Luna G, Ferrer E et al. Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine 26 (Suppl. 10), K17 –K28 (2008).
102. Gillison ML, Chaturvedi AK, Lowy DR. HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer 113 (10 Suppl.), 3036–3046 (2008).
103. Insinga RP, Liaw KL, Johnson LG, Madeleine MM. A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States. Cancer Epidemiol. Biomarkers Prev. 17 (7), 1611–1622 (2008).
104. Smith JS, Backes DM, Hoots BE, Kurman RJ, Pimenta JM. Human papillomavirus type-distribution in vulvar and vaginal cancers and their associated precursors. Obstet. Gynecol. 113 (4), 917–924 (2009).
105. Joura EA, Leodolter S, Hernandez-Avila M et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 369 (9574), 1693–1702 (2007).
106. Jenkins D. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention. Gynecol. Oncol. 110 (3 Suppl. 1), S18 –S25 (2008).
107. Hauspy J, Beiner M, Harley I, Ehrlich L, Rasty G, Covens A. Sentinel lymph node in vulvar cancer. Cancer 110 (5), 1015–1023 (2007).
108. de Hullu JA, van der Zee AG. [Surgical treatment of early-stage vulva carcinoma and the complications of the operation]. Ned. Tijdschr. Geneeskd. 149 (7), 336–342 (2005).